BridgeBio to Accelerate Attruby Launch with $1 Billion Funding

BridgeBio Pharma (BBIO) has secured up to $1 billion in preferred equity financing from Sixth Street Partners and others. The financing includes a conversion price of $137.79 per share, representing a premium of over 100% to the recent average share price, which is considered favorable in terms of capital costs. These funds will be used to support the commercial launch of Attruby (acoramidis), an ATTR-CM treatment that received FDA approval in November 2024. This move is seen as providing BridgeBio with the resources to compete effectively in the $5.4 billion market currently dominated by Pfizer's Vyndaqel.

United Therapeutics Acquires Thymmune to Expand Cell Therapy Pipeline

United Therapeutics (UTHR) has acquired Thymmune Therapeutics, a company developing cell therapies for Congenital Athymia. The deal includes an upfront payment of $140 million and milestone payments of $160 million, totaling $300 million. Thymmune's lead pipeline candidate, THY-100, is a thymus cell therapy candidate based on induced pluripotent stem cells (iPSC) and is currently in the preclinical stage. With only 17-24 patients in the U.S. annually, this ultra-rare disease market presents an opportunity for Thymmune to demonstrate the superiority of its platform against Enlivex's Rethymic, which has a list price of $2.7 million per administration.

Otsuka's Voyxact Phase 3 Trial Success Paves Way for Traditional Approval

Otsuka Pharmaceutical's Voyxact (sibeprenlimab), an IgA nephropathy (IgAN) treatment, has achieved positive final results in its Phase 3 trial. Voyxact is a monoclonal antibody that targets and inhibits APRIL, a key protein that contributes to kidney function deterioration. The trial demonstrated that Voyxact stabilized and improved kidney function over two years compared to placebo, providing data to support the conversion of its Accelerated Approval (received in late 2025) to Traditional Approval. With the IgAN treatment market expected to grow to over $6 billion annually, Voyxact is poised to significantly strengthen its market penetration by maximizing drug convenience and efficacy.

Vertex's Casgevy Receives FDA Approval for Use in Children Aged 2 and Older

Vertex Pharmaceuticals' (VRTX) CRISPR-based gene editing therapy, Casgevy (exagamglogene autotemcel), has received FDA approval for expanded use. This approval extends the treatment to children aged 2 and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT), making it the first gene therapy for this age group. The expanded approval is expected to provide treatment benefits to an additional 5,500 children in the U.S. Casgevy, which has faced some initial challenges in commercial growth due to the complexity of the manufacturing process, is now well-positioned to accelerate its commercial success with this expanded patient population.